Prognostic value of ATN Alzheimer biomarkers: 60‐month follow‐up results from the Argentine Alzheimer's Disease Neuroimaging Initiative

ALLEGRI, RICARDO F.; CHREM MÉNDEZ, PATRICIO; CALANDRI, ISMAEL; COHEN, GABRIELA; MARTÍN, MARIA EUGENIA; RUSSO, MARÍA JULIETA; CRIVELLI, LUCIA; PERTIERRA, LUCIA; TAPAJÓZ, FERNANDA; CLARENS, MARÍA FLORENCIA; CAMPOS, JORGE; NAHAS, FEDERICO E.; VÁZQUEZ, SILVIA; SURACE, EZEQUIEL; SEVLEVER, GUSTAVO

journal of alzheimer's disease

IOS Press

Lugar: Chicago; Año: 2020 vol. 12

1387-2877

Purpose: To describe results of the Amyloid, Tau, Neurodegeneration (ATN) researchframework classification in the Argentine-Alzheimer?s Disease Neuroimaging Initiative(arg-ADNI) cohort.Methods: Twenty-three patients with mild cognitive impairment (MCI), 12 dementia ofAlzheimer?s type (DAT), and 14 normal controls were studied following the ADNI2 protocol. Patients were categorized according to presence or absence of the biomarkers foramyloid beta (A𝛽; A: amyloid positron emission tomography [PET] scan or cerebrospinalfluid [CSF] A𝛽42), tau (T: CSF phosphorylated-tau), and neurodegeneration (N: CSFtotal-tau, fluorodeoxyglucose [FDG]-PET scan, or structural magnetic resonance imaging [MRI] scan).Results: A+T+N+ biomarker profile was identified at baseline in 91% of mild dementia patients, 20% of early MCI patients, 46% of late MCI patients, and 14% of controlsubjects. Suspected non-AD pathophysiology (SNAP, A-T-N+) was found in 8% of milddementia, 20% of early MCI, 15% of late MCI, and 7% of control subjects. Conversionrates to dementia after 5-year follow-up were 85% in A+T+N+ MCI patients and 50%in A-T-N+ patients.Conclusions: We present initial 5-year follow-up results of a regional ADNI based onAD biomarkers and the ATN classification.